Finding Relief After Years of Unbearable Pain from Sickle Cell Disease: Allan's Story
Allan Byamukama was one of the first 15 people in the world to receive a cutting-edge gene therapy for sickle cell disease.
Video: Meet Dr. Azar and learn about CRISPR gene therapy for sickle cell disease
Dr. Sharl Azar is a hematologist at the Massachusetts General Hospital and Harvard Medical School and the medical director of the Comprehensive Sickle Cell Disease Treatment Center. He received his medical degree from Oregon Health & Science University where he also completed his residency in internal medicine and his fellowship in hematology and medical oncology while also serving as Chief Fellow. He went on to complete an advanced fellowship in hemostasis and thrombosis at the University of California, San Diego. Dr. Azar is passionate about the care of patients with Sickle Cell Disease, Thalassemia, and other hemoglobin disorders. His work focuses on improving systems of care and political advocacy for patients living with sickle cell disease to build a true medical home while combatting inequities in health care. He also sees patients with bleeding and clotting disorders, disorders red cell and platelet function, and hemolysis.
Follow Dr. Azar on Twitter: @TheSickleDoc
Clinical Interests:
Treats:
Languages:
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Allan Byamukama was one of the first 15 people in the world to receive a cutting-edge gene therapy for sickle cell disease.